| Liu, Tianshu |
| Recruiting | 3 | 400 | RoW | Tonifying Spleen and Kidney Sequential Regimen, TSKSR, Placebo of 'Tonifying Spleen and Kidney Sequential Regimen, Placebo of TSKSR | Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing University of Chinese Medicine, Peking University Third Hospital, Beijing Chao Yang Hospital, Jiangsu Province Hospital of Traditional Chinese Medicine, Shanghai Zhongshan Hospital, Guangdong Provincial Hospital of Traditional Chinese Medicine, Tianjin Union Medical Center, Henan Provincial People's Hospital, Zhengzhou Hospital of Traditional Chinese Medicine, Peking University Cancer Hospital & Institute, Chongqing University Cancer Hospital, Civil Aviation General Hospital | Colon Cancer | 05/21 | 05/21 | | |
NCT04714190: A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression |
|
|
| Recruiting | 3 | 351 | RoW | RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection, Paclitaxel injection, Taxol, Irinotecan Hydrochloride Injection, CAMPTO, Apatinib Mesylate Tablets, Aitan | RemeGen Co., Ltd. | Gastric Cancer, HER2 Overexpressing Gastric Carcinoma | 12/24 | 06/25 | | |
COMPASSIOn-15, NCT05008783: A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma |
|
|
| Active, not recruiting | 3 | 610 | RoW | AK104, Oxaliplatin, Capecitabine, Placebo | Akeso | Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 08/24 | 04/25 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
NCT05180734: PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer |
|
|
| Active, not recruiting | 3 | 878 | RoW | JS001/Placebo, Postoperative Adjuvant Chemotherapy, JS001/placebo combine with Postoperative Adjuvant Chemotherapy | Shanghai Junshi Bioscience Co., Ltd. | Gastric or Esophagogastric Junction Adenocarcinoma | 06/26 | 07/28 | | |
NCT05019794: Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations |
|
|
| Recruiting | 2a | 80 | RoW | Infigratinib, BGJ398 | LianBio LLC | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Solid Tumor | 12/22 | 12/23 | | |
|
| Completed | 2 | 50 | RoW | GS+Toripalimab | Shanghai Zhongshan Hospital, Shanghai Junshi Bioscience Co., Ltd., OrigiMed | Biliary Tract Cancer | 12/21 | 03/22 | | |
NCT05143099: Phase II Study of Tislelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory mCRC |
|
|
| Active, not recruiting | 2 | 35 | RoW | TEC | Shanghai Zhongshan Hospital | Colorectal Neoplasms | 12/22 | 02/24 | | |
FRONT, NCT04296019: Fruquintinib as a Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 110 | RoW | Fruquintinib | Shanghai Zhongshan Hospital | Colo-rectal Cancer | 07/23 | 01/25 | | |
NCT06206278: Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma |
|
|
| Terminated | 2 | 6 | RoW | Infigratinib, BGJ398, BBP-831 | LianBio LLC | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 05/24 | 05/24 | | |
NCT05372120: A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations |
|
|
| Recruiting | 2 | 200 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Advanced Solid Tumor | 12/23 | 06/24 | | |
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. |
|
|
| Active, not recruiting | 2 | 103 | RoW | Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan | Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany | BRAF V600E, Metastatic Colorectal Cancer | 12/23 | 01/25 | | |
NCT05278351: Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC |
|
|
| Recruiting | 2 | 87 | RoW | Tislelizumab Combined With Cetuximab and Irinotecan, TEC, Third-line regimens | Shanghai Zhongshan Hospital | Colorectal Neoplasms Malignant | 04/24 | 12/25 | | |
NCT06587425: The Efficacy and Safety of LM-302 in Combination With Candonilimab and Capecitabine for First-Line Treatment in Patients With Unresectable Advanced, Recurrent, or Metastatic CLDN18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 2 | 50 | RoW | LM-302+Candonilimab+Capecitabine, ADC-Claudin18.2+AK104+Capecitabine | Shanghai Zhongshan Hospital | Gastric or Gastroesophageal Junction Adenocarcinoma | 07/25 | 12/26 | | |
NCT06632262: A Phase 2 Clinical Study of ABSK061 and ABSK043 |
|
|
| Not yet recruiting | 2 | 202 | RoW | ABSK061 + ABSK043, ABSK061+ABSK043 in combination with CAPOX | Abbisko Therapeutics Co, Ltd | HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors | 11/29 | 06/30 | | |
| Recruiting | 2 | 156 | RoW | SHR-A1811；SHR-1701；capecitabine；oxaliplatin | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | HER2+ Gastric Cancer/Gastroesophageal Junction Adenocarcinoma | 07/26 | 07/26 | | |
NCT05879055: A Study of PM8002 in Combination With Chemotherapy in Patients With NEN |
|
|
| Recruiting | 2 | 60 | RoW | PM8002, FOLFIRI | Biotheus Inc. | Neuroendocrine Neoplasm | 01/27 | 01/28 | | |
NCT05357196: PT-112 (Phosplatin's Platinum) Combine With Gemcitabine Injection for Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 68 | RoW | PT-112, Gemcitabine | SciClone Pharmaceuticals | Biliary Tract Cancer | 08/22 | 04/23 | | |
| Recruiting | 1/2 | 222 | RoW | SHR-1701, Famitinib | Jiangsu HengRui Medicine Co., Ltd. | Solid Tumor | 12/22 | 10/23 | | |
NCT05008445: Study of LM-102 in Patients With Advance Solid Tumors |
|
|
| Terminated | 1/2 | 11 | RoW | LM-102 Injection, LM-102 Injection combined with SOC | LaNova Medicines Development Co., Ltd., Shanghai Zhongshan Hospital, First Affiliated Hospital of Harbin Medical University, First Affiliated Hospital of Zhejiang University, Sir Run Run Shaw Hospital | Advanced Solid Tumor | 02/23 | 02/23 | | |
NCT05024214: Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors |
|
|
| Recruiting | 1/2 | 170 | RoW | Lenvatinib + Envafolimab, Sunitinib | 3D Medicines (Sichuan) Co., Ltd. | Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma | 12/24 | 12/24 | | |
NCT04612712: A Phase 1/2 Study of Donafenib in Combination With KN046 in Advanced Gastrointestinal Tumors |
|
|
| Recruiting | 1/2 | 42 | RoW | Donafenib Tosilate Tablets, KN046 Injection | Suzhou Zelgen Biopharmaceuticals Co.,Ltd, Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Gastrointestinal Tumors | 12/23 | 12/23 | | |
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 320 | RoW | TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab | Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb | Advanced Cancer | 02/25 | 05/25 | | |
NCT05205850: A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors |
|
|
| Recruiting | 1/2 | 135 | RoW | RC118-ADC, RC118 for injection | RemeGen Co., Ltd. | Advanced Solid Tumor | 09/25 | 12/25 | | |
CT041-ST-01, NCT04581473: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection |
|
|
| Recruiting | 1/2 | 192 | RoW | CT041 autologous CAR T-cell injection, CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）, Best support care(BSC) | CARsgen Therapeutics Co., Ltd., Peking University Cancer Hospital & Institute, Fudan University | Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma | 06/24 | 06/38 | | |
NCT06111326: BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 1/2 | 83 | RoW | BC3402 injection, Durvalumab injection | Biocity Biopharmaceutics Co., Ltd. | Hepatocellular Carcinoma | 08/24 | 05/26 | | |
NCT05383482: Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 |
|
|
| Active, not recruiting | 1/2 | 22 | RoW | Afuresertib, LAE002, Nab paclitaxel, Docetaxel, Sintilimab | Laekna Limited | Solid Tumor, NSCLC, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gastric and Gastroesophageal Junction Adenocarcinoma | 06/24 | 12/25 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
NCT05906524: KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 85 | RoW | KD6001, Tislelizumab, Bevacizumab | Shanghai Kanda Biotechnology Co., Ltd. | Advanced HCC, Other Solid Tumors | 04/25 | 12/25 | | |
NCT06038396: A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 48 | RoW | RC118, RC118 for injection, Toripalimab, Toripalimab injection, JS001, RC148 | RemeGen Co., Ltd. | Advanced Solid Tumor | 02/26 | 08/26 | | |
| Recruiting | 1b | 38 | RoW | ZN-c3, Study Drug | Zentera Therapeutics HK Limited | Solid Tumors | 06/22 | 06/23 | | |
NCT04689100: Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor |
|
|
| Recruiting | 1 | 259 | RoW | JMT101, FOLFIRI(Irinotecan, Leucovorin Calcium, and Fluorouracil); mFOLFOX6((Oxaliplatin, Leucovorin Calcium, and Fluorouracil);, FOLFIRI; mFOLFOX6; Irinotecan; | Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Advanced Solid Tumor | 12/21 | 06/22 | | |
NCT04381325: A Study of MSB0254 Injection in Advanced Solid Tumors |
|
|
| Terminated | 1 | 25 | RoW | MSB0254 Injection | Suzhou Transcenta Therapeutics Co., Ltd. | Advanced Solid Tumor | 06/22 | 06/22 | | |
NCT05173792: Study of AK119 in Subjects With Advanced Solid Tumors |
|
|
| Completed | 1 | 16 | RoW | AK119 | Akeso | Solid Tumor | 05/23 | 05/23 | | |
NCT05010694: GH35 Tablets for Advanced Solid Tumors: A Study on Safety and Early Results |
|
|
| Active, not recruiting | 1 | 18 | RoW | GH35 Tablet | Suzhou Genhouse Bio Co., Ltd. | Advanced Solid Tumors Harboring With G12C Mutation | 03/23 | 12/25 | | |
BL0006-101, NCT06247657: A Phase I Study to Assess the Safety and Tolerability of BL0006 for Patients With Advanced Solid Tumours |
|
|
| Recruiting | 1 | 66 | RoW | BL0006 | Shanghai Best-Link Bioscience, LLC | Advanced Solid Tumor | 10/24 | 05/25 | | |
NCT06225622: Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer |
|
|
| Recruiting | 1 | 78 | RoW | Irinotecan Liposome, Oxaliplatin, 5-FU, LV, Bevacizumab, Cetuximab | Shanghai Zhongshan Hospital, CSPC Ouyi Pharmaceutical Co., Ltd. | Metastatic Colorectal Cancer | 01/26 | 05/26 | | |
NCT05369312: Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients |
|
|
| Not yet recruiting | 1 | 230 | RoW | BPI-442096 | Betta Pharmaceuticals Co., Ltd. | Solid Tumor, Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer | 05/24 | 05/25 | | |
NCT05193721: A Clinical Study of the Safety and Tolerability of SHR-1901 in Subjects With Advanced Malignant Tumors |
|
|
| Active, not recruiting | 1 | 25 | RoW | SHR-1901 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Malignant Tumors | 06/24 | 08/24 | | |
| Recruiting | 1 | 108 | RoW | IMM27M, IMM2510 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Advanced Solid Tumors, HCC | 01/26 | 01/26 | | |
NCT05627063: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 169 | US, RoW | ABSK121-NX | Abbisko Therapeutics Co, Ltd | Solid Tumor | 03/25 | 06/25 | | |
NCT05886374: A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 81 | RoW | HMPL-415S1 | Hutchmed | Advanced Malignant Solid Tumors | 05/25 | 06/26 | | |
NCT05501912: A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors |
|
|
| Terminated | 1 | 20 | RoW | ABM-1310 | ABM Therapeutics Shanghai Company Limited | Advanced Solid Tumor, BRAF V600 Mutation | 06/24 | 06/24 | | |
| Not yet recruiting | 1 | 410 | RoW | NBL-015 | NovaRock Biotherapeutics, Ltd | Advanced Solid Tumors | 12/25 | 12/25 | | |
NCT03001726: To Observe the Efficacy and Safety by Comparing Chemotherapy(Docetaxel, Oxaliplatin Plus S1 ) Followed With Radical Resection Versus Chemotherapy Alone in Advanced Gastric Cancer With Single Non-curable Factor. |
|
|
| Enrolling by invitation | N/A | 228 | RoW | Gastrectomy, oxaliplatin, Eloxatin, S1, tegafur, Docetaxel, Taxotere | Shanghai Zhongshan Hospital | Gastric Cancer | 06/22 | 12/23 | | |
